Eli Lilly Reports the MHRA’s Approval of Kisunla (Donanemab) to Treat Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
Shots:
- The UK’s MHRA has approved Kisunla to treat mild cognitive impairment & dementia due to AD in patients who are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers
- Approval was based on P-III (TRAILBLAZER-ALZ 2) trial assessing Kisunla vs PBO in patients (n=1,736) with early symptomatic AD, showing significant slowing of cognitive & functional decline. Results were published in the JAMA
- Kisunla is further being assessed in TRAILBLAZER-ALZ 3 study to prevent progression in patients with preclinical AD, registrational TRAILBLAZER-ALZ 5 trial for early symptomatic AD in China & Korea as well as TRAILBLAZER-ALZ 6 study exploring ARIA via novel MRI sequences, blood-based biomarkers & different dosing regimens
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Highlights 1 Year Analysis from the P-III (VIVID-1) Trial of Mirikizumab for Treating Crohn's Disease at UEG Week 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
